The Rare Diseases Forum held its second discussion in a series for the Conducting Clinical Trials Amid COVID-19 working group on July 9, 2020. This working group will focus on the challenges in conducting clinical trials for rare diseases amid the COVID-19 pandemic and, as possible, document best practices and develop recommendations. This group will also explore how to address unplanned changes in clinical trials in rare diseases affected by COVID-19 and other potential future health emergencies and pandemics, while maintaining the scientific integrity and interpretability of study results.
Registrants for this discussion represented patients, advocacy organizations, academia, federal agencies, industry, professional societies, and other relevant entities. This discussion focused on the statistical considerations due to the impact of COVID-19 on clinical trials.
Agenda
Summary Notes
Presentations
Soon to come
Registrants for this discussion represented patients, advocacy organizations, academia, federal agencies, industry, professional societies, and other relevant entities. This discussion focused on the statistical considerations due to the impact of COVID-19 on clinical trials.
Agenda Summary NotesPresentations
Soon to come